Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 508Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Comprehensive analysis of the clinical immuno-oncology landscape

Open access
Tang, J., Shalabi, A., Hubbard-Lucey, V.M.·2018·Annals of Oncology

Abstract

Advances from immuno-oncology (IO) are changing the standard of care of many types of cancer, and the paradigm of cancer treatments and drug development is being rewritten on a regular basis. Moreover, an unprecedented number of new investigational agents and companies are entering the field of IO. As such, it has become challenging for oncology physicians conducting clinical trials, industry veterans developing IO drugs, and even regulators reviewing novel IO agents to keep track of the rapidly evolving landscape. To help the key stake holders in the field understand the latest IO landscape, we sought to present an unbiased, neutral, scientifically curated, and timely updated analysis of all the current IO agents in clinical development and the clinical trials testing these agents. We based our analyses on information collected from numerous trusted and publicly available sources. We have developed two databases. One database tracks 2004 IO agents (940 in clinical stage and 1064 in preclinical stage) against 303 targets, from 864 companies; the other tracks 3042 active clinical trials of these agents with a target enrollment of 577 076 patients. This report provides key analyses of these data. Furthermore, we will discuss a number of important and actionable trends in the current IO landscape: a large number of companies developing agents against the same IO targets; a rapid increase in the number of anti-PD-1/L1 combination studies, many of which are testing the same combin…

Overview

Integrity signals

Registry

Crossref · 10.1093/annonc/mdx755

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 29 references

Cited by

See all 508

Metadata

Authors
Tang, J., Shalabi, A., & Hubbard-Lucey, V. M.
Affiliations
Cancer Research Institute (US)
Corresponding author
Hubbard-Lucey, V.M.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2018-01
Volume
29
Issue
1
Pages
84-91
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2774533844
Cited by
508
References
29
Citations by year
2026: 12 · 2025: 35 · 2024: 30 · 2023: 40 · 2022: 57 · 2021: 87 · 2020: 99 · 2019: 88 · 2018: 56
FWCI
29.66
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
cancer immunotherapy, clinical trials, investigator-initiated trials, anticancer drug development, research duplication, clinical trial recruitment
MeSH terms
Antineoplastic Agents, Immunological, Clinical Trials as Topic, Humans, Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comprehensive analysis of the clinical immuno-oncology landscape. https://app.cochat.ai/papers/10.1093/annonc/mdx755
The paper
Tang, J., Shalabi, A., & Hubbard-Lucey, V. M. (2018). Comprehensive analysis of the clinical immuno-oncology landscape. Annals of Oncology. https://doi.org/10.1093/annonc/mdx755

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.